AR066150A1 - SUBSTITUTED SILILED BENZOTRIAZOLLILFENOL COMPOUNDS - Google Patents

SUBSTITUTED SILILED BENZOTRIAZOLLILFENOL COMPOUNDS

Info

Publication number
AR066150A1
AR066150A1 ARP080101773A ARP080101773A AR066150A1 AR 066150 A1 AR066150 A1 AR 066150A1 AR P080101773 A ARP080101773 A AR P080101773A AR P080101773 A ARP080101773 A AR P080101773A AR 066150 A1 AR066150 A1 AR 066150A1
Authority
AR
Argentina
Prior art keywords
mono
unsubstituted
substituted
radical
saturated
Prior art date
Application number
ARP080101773A
Other languages
Spanish (es)
Inventor
Capa Olga Gorchs
Jordi Corbera-Arcona
Costa David Panyella
Cabanas Carlos Ramon Trullas
Alonso Oscar Jimenez
Original Assignee
Isdin Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38462420&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066150(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isdin Sa filed Critical Isdin Sa
Publication of AR066150A1 publication Critical patent/AR066150A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un proceso para su preparacion, una composicion farmacéutica y/o cosmética que comprende estos compuestos, su uso para la preparacion de una composicion farmacéutica para la profilaxis y/o el tratamiento de enfermedades causadas por y/o asociadas con la exposicion a radiacion ultravioleta, su uso para la profilaxis y/o el cuidado contra condiciones no deseadas de la piel, así como su uso como fotoestabilizador en composiciones de polímeros. Reivindicacion 1: Al menos un compuesto de benzotriazolilfenol sililado substituido de la formula general (1) en donde k = 0 o 1; q = 1 o 2; R1 y R2, independientemente uno de otro, representa cada uno un átomo de hidrogeno; un átomo de halogeno; -NO2; -OR8; -SR9; -CN; -NR10R11; -C(=O)-OR12; -C(=O)-NR14R15; -OC(=O)R16; -NR17-C(=O)R18; -NR19-C(=O)-O-R20; -S(=O)2-R21; -S(=O)2-O-R22; -S(=O)2-NR23R24; un radical alifático C1-18 lineal o ramificado, saturado, insustituido o al menos mono-sustituido; un radical arilo insustituido o al menos mono-sustituido, que puede estar unido por un grupo alquileno lineal o ramificado, insustituido o al menos mono- sustituido y/o que puede estar condensado con un sistema de anillos insustituido o al menos mono-sustituido, saturado o aromático, mono- o bicíclico; o r1 y R2 están condensados para formar juntos un sistema de anillos adicional aromático mono- o policíclico que tiene de 4 a 10 átomos de carbono; R3 representa un radical cicloalifático insustituido o al menos mono-sustituido, saturado, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar condensado con un sistema de anillos insustituido o al menos mono-sustituido, saturado o aromático, mono- o bicíclico; o un radical arilo o heteroarilo insustituido o al menos mono-sustituido, que puede estar condensado con un sistema de anillos insustituido o al menos mono- sustituido, saturado o aromático, mono- o bicíclico; R4 representa un átomo de hidrogeno; un radical alifático C1-18 lineal o ramificado, saturado, insustituido o al menos mono-sustituido; con la salvedad de que si q = 1, entonces k = 1; R5 y R6 y R7, independientemente uno de otro, representa cada uno un radical alifático C1-18 lineal o ramificado, saturado, insustituido o al menos mono-sustituido; un radical alifático -O-C1-18 lineal o ramificado, saturado, insustituido o al menos mono-sustituido; un radical cicloalifático saturado insustituido o al menos mono-sustituido; un radical arilo insustituido o al menos mono- sustituido, que puede estar condensado con un sistema de anillos aromático insustituido o al menos mono- sustituido, mono- o bicíclico; o R5, R6 y R7, independientemente uno de otro, representa cada uno un radical de la formula general (2) en donde p = 0, 1, 2 o 3; R25, R26, R27, R28 y. R29, independientemente uno de otro, representa cada uno un radical alifático C1-18 lineal o ramificado, saturado, insustituido o al menos mono- sustituido; un radical alifático -O-C1-8 lineal o ramificado, saturado, insustituido o al menos mono- sustituido; un radical arilo insustituido o al menos mono-sustituido; o un radical -O-Si(R30)3, representando R30 un radical alquilo C1-18 lineal o ramificado, insustituido o al menos mono-sustituido; un radical alquilo -O-C1-18 lineal o ramificado, insustituido o al menos mono-sustituido; o un radical arilo insustituido o al menos mono-sustituido; con la condicion de que si q = 1 y al mismo tiempo k = 1, al menos uno de los radicales R5, R6 y R7 representa un radical de la formula general (2) como se ha definido arriba; o, con la salvedad de que si q = 2, entonces k = 0; R7 representa un radical de la formula general (3) en donde m = 0, 1, 2, 3, 4 o 5; X representa un átomo de oxígeno o un radical alquileno C1-6 insustituido o al menos mono-sustituido; R31, R32, R33 y R34, independientemente uno de otro, representa cada uno un radical alifático C1-18 lineal o ramificado, saturado, insustituido o al menos mono-sustituido; un radical alifático -O-C1-18 lineal o ramificado, saturado, insustituido o al menos mono-sustituido; un radical cicloalifático saturado insustituido o al menos mono-sustituido; un radical arilo insustituido o al menos mono- sustituido, que puede estar condensado con un sistema de anillos aromático mono- o bicíclico insustituido o al menos mono-sustituido; o un radical -O-Si(R30)3, representando R30 un radical alquilo C1-18 lineal o ramificado, insustituido o al menos mono-sustituido; un radical alquilo -O-C1-18 lineal o ramificado, insustituido o al menos mono-sustituido; o un radical arilo insustituido o al menos mono- sustituido; R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R23 y R24 independientemente uno de otro, representa cada uno un átomo de hidrogeno; un radical alifático C1-18 lineal o ramificado, saturado, insustituido o al menos mono- sustituido; un radical cicloalifático insustituido o al menos mono-sustituido, saturado, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo insustituido o al menos mono- sustituido; R20 y R21, independientemente uno de otro, representa cada uno un radical alifático C1-18 lineal o ramificado, saturado, insustituido o al menos mono-sustituido, un radical cicloalifático insustituido o al menos mono-sustituido, saturado, que contiene opcionalmente al menos un heteroátomo. como miembro del anillo, o un radical arilo insustituido o al menos mono-sustituido; y R22, independientemente uno de otro, representa cada uno un átomo de hidrogeno; o un radical cicloalifático insustituido o al menos mono-sustituido, saturado, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo insustituido o al menos mono-sustituido; opcionalmente en forma de uno de sus estereoisomeros, preferiblemente enantiomeros o diastereoisomeros, su racemato o en la forma de una mezcla de al menos dos de sus estereoisomeros, preferiblemente enantiomeros o diastereoisomeros, en cualquier relacion de mezcla, o una sal, preferiblemente una sal correspondiente, fisiologicamente aceptable, o un solvato correspondiente.A process for its preparation, a pharmaceutical and / or cosmetic composition comprising these compounds, its use for the preparation of a pharmaceutical composition for the prophylaxis and / or treatment of diseases caused by and / or associated with exposure to ultraviolet radiation, its use for prophylaxis and / or care against unwanted skin conditions, as well as its use as a photostabilizer in polymer compositions. Claim 1: At least one substituted silylated benzotriazolylphenol compound of the general formula (1) wherein k = 0 or 1; q = 1 or 2; R1 and R2, independently of each other, each represents a hydrogen atom; a halogen atom; -NO2; -OR8; -SR9; -CN; -NR10R11; -C (= O) -OR12; -C (= O) -NR14R15; -OC (= O) R16; -NR17-C (= O) R18; -NR19-C (= O) -O-R20; -S (= O) 2-R21; -S (= O) 2-O-R22; -S (= O) 2-NR23R24; a linear or branched, saturated, unsubstituted or at least mono-substituted C1-18 aliphatic radical; an unsubstituted or at least mono-substituted aryl radical, which may be joined by a linear or branched, unsubstituted or at least mono-substituted alkylene group and / or that may be fused to an unsubstituted or at least mono-substituted ring system, saturated or aromatic, mono- or bicyclic; or r1 and R2 are condensed together to form an additional mono- or polycyclic aromatic ring system having 4 to 10 carbon atoms; R3 represents an unsubstituted or at least mono-substituted, saturated cycloaliphatic radical, optionally containing at least one heteroatom as a member of the ring, which may be condensed with an unsubstituted or at least mono-substituted, saturated or aromatic, mono- ring system. or bicyclic; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be fused to an unsubstituted or at least mono-substituted, saturated or aromatic, mono- or bicyclic ring system; R4 represents a hydrogen atom; a linear or branched, saturated, unsubstituted or at least mono-substituted C1-18 aliphatic radical; with the proviso that if q = 1, then k = 1; R5 and R6 and R7, independently of each other, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted C1-18 aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted aliphatic radical -O-C1-18; an unsubstituted or at least mono-substituted saturated cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl radical, which may be fused to an unsubstituted or at least mono-substituted, mono- or bicyclic aromatic ring system; or R5, R6 and R7, independently of each other, each represents a radical of the general formula (2) wherein p = 0, 1, 2 or 3; R25, R26, R27, R28 and. R29, independently of each other, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted C1-18 aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted aliphatic radical -O-C1-8 radical; an unsubstituted or at least mono-substituted aryl radical; or a -O-Si (R30) 3 radical, R30 representing a linear or branched, unsubstituted or at least mono-substituted C1-18 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted alkyl radical -O-C1-18; or an unsubstituted or at least mono-substituted aryl radical; with the proviso that if q = 1 and at the same time k = 1, at least one of the radicals R5, R6 and R7 represents a radical of the general formula (2) as defined above; or, with the proviso that if q = 2, then k = 0; R7 represents a radical of the general formula (3) where m = 0, 1, 2, 3, 4 or 5; X represents an oxygen atom or an unsubstituted or at least mono-substituted C1-6 alkylene radical; R31, R32, R33 and R34, independently of each other, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted C1-18 aliphatic radical; a linear or branched, saturated, unsubstituted or at least mono-substituted aliphatic radical -O-C1-18; an unsubstituted or at least mono-substituted saturated cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl radical, which may be fused to an unsubstituted or at least mono-substituted mono- or bicyclic aromatic ring system; or a -O-Si (R30) 3 radical, R30 representing a linear or branched, unsubstituted or at least mono-substituted C1-18 alkyl radical; a linear or branched, unsubstituted or at least mono-substituted alkyl radical -O-C1-18; or an unsubstituted or at least mono-substituted aryl radical; R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R23 and R24 independently of each other, each represents a hydrogen atom; a linear or branched, saturated, unsubstituted or at least mono-substituted C1-18 aliphatic radical; an unsubstituted or at least mono-substituted, saturated cycloaliphatic radical, optionally containing at least one heteroatom as a member of the ring, or an unsubstituted or at least mono-substituted aryl radical; R20 and R21, independently of each other, each represents a linear or branched, saturated, unsubstituted or at least mono-substituted C1-18 aliphatic radical, an unsubstituted or at least mono-substituted cycloaliphatic radical, saturated, optionally containing at least a heteroatom. as a member of the ring, or an unsubstituted or at least mono-substituted aryl radical; and R22, independently of each other, each represents a hydrogen atom; or an unsubstituted or at least mono-substituted, saturated cycloaliphatic radical, optionally containing at least one heteroatom as a ring member, or an unsubstituted or at least mono-substituted aryl radical; optionally in the form of one of its stereoisomers, preferably enantiomers or diastereoisomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereoisomers, in any mixing ratio, or a salt, preferably a corresponding salt , physiologically acceptable, or a corresponding solvate.

ARP080101773A 2007-04-27 2008-04-25 SUBSTITUTED SILILED BENZOTRIAZOLLILFENOL COMPOUNDS AR066150A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07384024 2007-04-27

Publications (1)

Publication Number Publication Date
AR066150A1 true AR066150A1 (en) 2009-07-29

Family

ID=38462420

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101773A AR066150A1 (en) 2007-04-27 2008-04-25 SUBSTITUTED SILILED BENZOTRIAZOLLILFENOL COMPOUNDS

Country Status (4)

Country Link
AR (1) AR066150A1 (en)
CL (1) CL2008001211A1 (en)
PE (1) PE20090242A1 (en)
WO (1) WO2008131921A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003059B1 (en) * 2010-10-25 2017-04-25 Oreal process for preparing 2-hydroxyphenyl alkenyl benzotriazole compound and process for preparing siloxane compounds containing 2-hydroxyphenyl benzotriazole function
US20140163229A1 (en) 2011-04-07 2014-06-12 Cornell University Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same
CA2991489A1 (en) 2015-07-07 2017-01-12 3M Innovative Properties Company Substituted benzotriazole phenolate salts and antioxidant compositions formed therefrom
KR102662840B1 (en) 2015-07-07 2024-05-03 쓰리엠 이노베이티브 프로퍼티즈 캄파니 Polymer matrix with ionic additives
JP6975705B2 (en) 2015-07-07 2021-12-01 スリーエム イノベイティブ プロパティズ カンパニー Substituted benzotriazole phenol
CN115232554A (en) * 2022-08-15 2022-10-25 郑州中原思蓝德高科股份有限公司 Corrosion-resistant elastic bonding protection composition and protection material

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2695560B1 (en) * 1992-09-17 1994-11-04 Oreal Photostable filtering cosmetic composition containing a UV-A filter and a filter polymer of the benzotriazole silicone type.
DE19726184A1 (en) * 1997-06-20 1998-12-24 Beiersdorf Ag Oil-in-water or multiple emulsion with high concentration of suspended UVB filter
DE10155963A1 (en) * 2001-11-09 2003-05-22 Beiersdorf Ag Cosmetic and dermatological light protection formulations containing hydroxybenzophenones, triazine and / or benzotriazole derivatives

Also Published As

Publication number Publication date
PE20090242A1 (en) 2009-04-04
WO2008131921A1 (en) 2008-11-06
CL2008001211A1 (en) 2009-08-07

Similar Documents

Publication Publication Date Title
PE20181045A1 (en) USEFUL COMPOUNDS AS IMMUNOMODULATORS
PE20220567A1 (en) NEW PIPERIDINIL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR036492A1 (en) INHIBITORS OF THE 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH INHIBITORS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DEPENDING ANDROGEN DISEASES
PE20190709A1 (en) DERIVED FROM PIRAZOLOPIRIDINA THAT HAS THE AGONIST EFFECT OF THE GLP-1 RECEPTOR
AR066150A1 (en) SUBSTITUTED SILILED BENZOTRIAZOLLILFENOL COMPOUNDS
CY1119015T1 (en) 4'-AZID-3'FLUORABLE NUCLEOZIDE SUBSTITUTES PRODUCER AS HCV RNA COPYPRISES
AR083849A1 (en) ESPIRO-OXINDOL MDM2 ANTAGONISTS
AR088919A2 (en) DERIVATIVES OF PIRAZOL, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND USE
RU2014129742A (en) DERIVATIVES OF BENZENESULFONAMIDE AS RORC MODULATORS
TNSN07471A1 (en) Novel 2,4 - dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
CL2004000917A1 (en) COMPOUNDS DERIVED FROM TIAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF DISEASES MEDIATED BY DOSFATIDILNOSITOL 3-KINASE SUCH AS RESPIRATORY DISEASES, ALLERGIES, Rheumatoid Arthritis, OSTEOA
AR061739A1 (en) NEW NAFTALENIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR063804A1 (en) AZONIABICICLO COMPOUNDS [2.2.2] OCTANO
UY28526A1 (en) GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
AR054809A1 (en) COMPOUNDS OF AMINO -5-HETEROARILO (5 MEMBERS) IMIDAZOLONE AND ITS USE FOR THE MODULATION OF B-SECRETASE
AR062357A1 (en) DERIVATIVES OF PHENYLL, PYRIDINE AND QUINOLINE, PHARMACEUTICAL COMPOSITIONS AND ITS USE AS MEDICATIONS
UY28157A1 (en) GLUCOCORTICOID MIMETICS METHODS FOR THEIR DEVELOPMENT PHARMACEUTICAL COMPOSITIONS AND THEIR USES
AR079205A1 (en) MORPHOLINOTIAZOLS AS POSITIVE ALOSTERIC MODULATORS ALFA 7
DOP2007000022A (en) DERIVATIVES OF TRICYCLIC N-HETEROARIL-CARBOXAMIDS CONTAINING A REST BENCIMIDAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
AR069813A1 (en) DERIVATIVES OF 2- AMINO-PYRIMIDINE, A PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARATION OF THE COMPOUND AND USE OF IT TO PREPARE A MEDICINAL PRODUCT
AR057408A1 (en) NIACINE RECEIVER AGONISTS COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
AR054863A1 (en) DERIVATIVES OF 1H-PIRROLO [3, 4-C] PIRAZOL, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PROFILAXIS OF DISEASES ASSOCIATED WITH THE COAGULATION X FACTOR
AR064414A1 (en) DERIVATIVES OF 1-AZONIABICICLO [2, 2, 2] OCTANO AND 1-AZABICICLO [2, 2, 2] OCT-3-ILO, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, PROCEDURE FOR OBTAINING THE SAME, ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF COPD AND A PHARMACEUTICAL PRODUCT THAT
AR019789A2 (en) COMPOUNDS DERIVED FROM ERYTHROMYCIN, COMPOSITIONS THAT CONTAIN THEM, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT
AR062737A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM ARIL-AZABICICLO, CORRESPONDING COMPOUND AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FB Suspension of granting procedure